IDUN Pharmaceuticals, Inc.

Therapeutic applications focused on inhibiting caspase activity as treatments for liver disease and inflammation

(1994)

Management:
Steven Mento, President & CEO

UM Inventor(s):
Gabriel Nunez

Funding parties:
Aberdare Ventures, Abbott Laboratories, Accel Partners, ARCH Venture Partners, BioVeda Capital, Delphi Ventures, Elan International Services, GeneChem, Hambrecht & Quest Capital Management, Institutional Venture Partners & Affiliated Entitites, MPM Capital, Novartis Pharma AG, Pacific Rim Ventures, Prospect Venture Partners, RBC Capital Partners, Sorrento Venture, Sutter Hill Ventures, Temasek Holdings, Venrock Associates, Ventana Capital Management

Acquisitions:
Pfizer, Inc. [NYSE:PFE] in 2005